Bibliography:
1 Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell
disease. Nat Rev Dis Prim 2018;4. https://doi.org/10.1038/nrdp.2018.10.
2 Ohba Y, Hattori Y, Harano T, Harano K, Fukumaki Y, Ideguchi H. β- Thalassemia mutations
in Japanese and Koreans. Hemoglobin 1997;21:191-200.
https://doi.org/10.3109/03630269708997524
3 Thein SL. Genetic basis and genetic modifiers of β-thalassemia and sickle cell disease. Adv.
Exp. Med. Biol., vol. 1013, Springer New York LLC; 2017, p. 27-57.
https://doi.org/10.1007/978-1-4939-7299-9_2.
SCIENTIFIC PROGRAMME
SESSION I
BONE MARROW
RESPONSE TO VIRAL
INFECTIONS
SESSION II
HAEMATOLOGICAL
RESPONSE TO SARS
COV2 INFECTION
SESSION III
DYSERYTHROPOIESIS IN
CLONAL HAEMOPOIESIS
AND MDS
SESSION IV
ERYTHROPOIESIS
CONTROL
SESSION V
ERYTHROPOIESIS
CONTROL : PHASE 2
SESSION VI
IRON METABOLISM
AND ERYTHROPOIESIS
SESSION VII
INHERITED
DYSERYTHROPOIESIS
SESSION VIII
GENE THERAPY/EDITION
SESSION IX – DRUGS
AND INEFFECTIVE
ERYTHROPOIESIS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES